Riyadh — Tabuk Pharmaceuticals, a leading Saudi pharmaceuticals company, and Prestige Biopharma, a publicly listed company based in Singapore focusing on late-stage clinical development of new antibody therapeutics and biosimilars, today announced an exclusive licensing and distribution agreement for the commercialization of Prestige BioPharma’s Trastuzumab biosimilar (HD201; Tuznue™) in the MENA region.
Tuznue™ is a monoclonal antibody (mAb) biosimilar to Roche’s Herceptin® (trastuzumab), which is used to treat patients with HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. The European Medicines Agency (EMA) has accepted a Marketing Authorisation Application for Tuznue™ for review, based on positive top-line results from global clinical trials.
The licensing agreement provides Tabuk with exclusive rights to commercialize and distribute Tuznue™ in the MENA region, leveraging the company’s strong sales and marketing capabilities and experience in successfully bringing key pharmaceutical products to market.
Under the terms of the licensing agreement:
- Tabuk will be responsible for the registration and commercialization of Tuznue™ in the MENA markets.
- Prestige Biopharma will be responsible for product supply.
This agreement augments Tabuk’s biotech-immunology strategy in MENA and adds a specialized biosimilar product to their portfolio.
Basel Ziyadeh, CEO of Tabuk Pharmaceuticals, commented:
“At Tabuk Pharmaceuticals, we are excited to form this partnership with Prestige Biopharma which builds on our market-leading position and advances our strategic objective of growing our specialty business in KSA and the MENA region. This is another important step forward for Tabuk in commercializing complex and specialty medicines that will benefit patients in critical disease areas and position our business for continued long-term growth.”
Lisa S. Park, CEO of Prestige BioPharma, commented:
“We are very pleased to establish a partnership with Tabuk Pharmaceuticals for selected MENA markets. As the largest private Saudi Pharmaceutical company, Tabuk is an ideal partner to commercialize our lead biosimilar in the MENA markets. With this partnership, we look forward to further strengthening the value of our biosimilar programs in global markets.”